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L
ast year the European 
Parliament and Council formed 
the European and Developing 
Countries Clinical Trials Partnership 
(EDCTP). The aim of this new funding 
body, which has a budget of  400 
million spread over ﬁ  ve years, is a noble 
one: to fund research in developing 
countries, particularly in Africa, that 
contributes to the development of 
affordable prophylactics and drugs for 
HIV/AIDS, tuberculosis, and malaria. 
Unfortunately, the organization 
has not got off to an auspicious start. 
Its executive director, Piero Olliaro, 
was ousted from power at the ﬁ  rst 
EDCTP annual forum at the end of 
September. There have been rumblings 
of discontent among grant applicants 
who say that the ﬁ  rst round of grant 
assessments was administered poorly. 
And not-for-proﬁ  t organizations that 
would like to partner with EDCTP have 
been left in the dark regarding whom 
to speak to at the organization.
This omission is signiﬁ  cant because 
partnership is one of the key tenets 
of the EDCTP. European research 
agencies are slowly beginning to realize 
that they need to cooperate with each 
other if they are to be competitive 
with the United States. The history of 
many European countries is such that 
Europe has much stronger ties with 
Africa than does the United States, 
so it makes political sense for the 
European Union to fund research that 
provides a springboard for European 
researchers to compete effectively with 
US scientists.
Crucially, the EDCTP was also 
set up to enable European and 
African scientists to work together as 
equal partners. There is increasing 
recognition that the paternalistic, 
colonial attitude that pervaded 
“tropical medicine” in the past just will 
not do. The EDCTP hoped to change 
that by having a Partnership Board that 
contains equal numbers of African and 
European representatives. However, 
the EDCTP Assembly, which contains 
a representative from each of 14 EU 
member states but none from African 
countries, has the power to veto the 
decisions of the Partnership Board, 
which is supposedly the scientiﬁ  c 
decision-making authority.  
Doing clinical trials in Africa is 
far from easy. There are too few 
adequately resourced research 
centers, and those that do consistently 
perform well are oversubscribed. 
Therefore, there is a clear need for 
“capacity building”—development 
of a research infrastructure, in terms 
of both equipment and personnel, 
that is capable of coping with the 
challenges of clinical trials. The EDCTP 
hopes to contribute to this essential 
endeavor by funding clinical trials that 
are sustainable in the long term. In 
particular, it believes that the best way 
to train a new generation of African 
scientists is by teaching them on the 
job, that is, involving them fully in the 
planning and execution of the trial, 
rather than ﬂ  ying in European experts 
who leave as soon as the trial is ﬁ  nished. 
A commitment from European 
researchers to be engaged for the long 
term is essential for the success of these 
projects. In addition, partnerships need 
to be brokered with national programs 
in Africa to ensure that the new 
capacity can be sustained over time. 
The end goal is to produce centers 
of excellence that are run by Africans 
doing internationally recognized 
research that conforms to Good 
Clinical Practice guidelines. But this 
will only happen if African researchers 
are treated as equal partners and are 
allowed to be fully engaged in the 
projects that are taking place in their 
countries.
So can the EDCTP work, or is it 
doomed to failure? In many ways the 
organization has a great deal going 
for it. Although the budget of  400 
million spread over ﬁ  ve years is tiny 
considering the combined burden of 
HIV/AIDS, tuberculosis, and malaria, 
it is important to remember that it is 
the biggest single European project 
for clinical trials in Africa. In many 
ways the EDCTP is a demonstration 
project: if some success can be achieved 
it is very likely that additional funds 
will follow. The project is certainly 
strengthened by the involvement of 
Pascoal Mocumbi, the former prime 
minister of Mozambique, as High 
Representative of the project. Mocumbi 
is highly respected by the global-health 
community and carries considerable 
weight with African politicians. 
Mobilization of political will within 
Africa will be essential if research 
capacity is to be sustained for the long 
term. 
On the downside, it seems clear to 
most insiders that the management 
structure needs to be radically 
changed and partnership with other 
organizations needs to be improved. 
The EDCTP Assembly met on October 
28 and 29 to discuss these issues and 
to elect a new leader.  At the time 
this editorial went to press, there was 
still no public announcement of the 
outcome of this meeting. In addition, 
the political inﬁ  ghting that pervades 
European politics at all levels needs 
to be controlled, or at least managed 
effectively. This might be a tall order, 
but it is essential if this worthwhile and 
high-proﬁ  le project is to succeed.  
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The EDCTP was set up 
to enable European and 
African scientists to 
work together as equal 
partners.